Cognition Therapeutics (CGTX) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cognition Therapeutics (CGTX) has outperformed Coherus Oncology (CHRS) over the past year, losing 58.1% versus a loss of 68.1%. Over five years, CGTX leads with a -93.5% price change compared with -98.0% for CHRS. Coherus Oncology is the larger company by market cap ($57.1 million vs $55.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | CHRS |
|---|---|---|
| Share price | $0.5822 | $0.3698 |
| Market cap | $55.37M | $57.15M |
| 1-day change | -3.06% | -4.47% |
| YTD return | -56.87% | -73.96% |
| 1-year return | -58.12% | -68.12% |
| 5-year return | -93.47% | -97.99% |
| EPS (TTM) | $-0.16 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $42.17M |
| Revenue growth (YoY) | — | +59.81% |
| Net income (latest FY) | $-23.49M | $168.02M |
| Gross margin | — | 67.24% |
| Operating margin | — | -429.51% |
| Net margin | — | 398.43% |
| 52-week high | $1.81 | $2.62 |
| 52-week low | $0.55 | $0.3628 |
| Distance from 52-week high | -67.83% | -85.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +471.97% | +1995.73% |
| Average volume | 464.94K | 1.80M |
| Shares outstanding | 95.10M | 154.54M |
| Employees | 14 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGTX has outperformed CHRS by 10.0 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
CGTX vs CHRS FAQ
Which is bigger, Cognition Therapeutics or Coherus Oncology?
Coherus Oncology (CHRS) is larger, with a market capitalization of $57.15M compared with $55.37M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or CHRS?
CGTX returned -58.12% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and Coherus Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.